GlassScriptPhysician profile
Amanda Van Wyk
NPI 1700423894
$543.30
in general payments reported to CMS, 2019-2025
11 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $40.71 · 2023: $105 · 2024: $48.37 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $138.35 | 2021-2022 | |
| Dermavant Sciences, INC. | $100.35 | 2023-2024 | Vtama |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.32 | 2021-2024 | Lifevest |
| Leo Pharma INC. | $66.94 | 2025 | Adbry |
| Botanix Sb INC | $42.61 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $30.00 | 2021 | |
| Abbott Laboratories | $19.78 | 2023 | Cardiomems |
| Pfizer INC. | $18.05 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $13.83 | 2022 | |
| Boston Scientific Corporation | $12.38 | 2021 | |
| Organon LLC | $4.69 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Van Wyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.